PTC Therapeutics, Inc. (PTCT)
Market Cap | 2.70B |
Revenue (ttm) | 927.56M |
Net Income (ttm) | -579.22M |
Shares Out | 76.70M |
EPS (ttm) | -7.68 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 700,036 |
Open | 36.50 |
Previous Close | 35.77 |
Day's Range | 35.08 - 37.32 |
52-Week Range | 17.53 - 42.63 |
Beta | 0.70 |
Analysts | Hold |
Price Target | 33.93 (-3.47%) |
Earnings Date | Aug 1, 2024 |
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pip... [Read more]
Financial Performance
In 2023, PTCT's revenue was $937.82 million, an increase of 34.20% compared to the previous year's $698.80 million. Losses were -$626.60 million, 12.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for PTCT stock is "Hold." The 12-month stock price forecast is $33.93, which is a decrease of -3.47% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/a/8/press12-2490959.jpg)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J. , June 21, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 17, 2024, the company approved non-statutory stock options to purchase an aggregate of 1...
![](https://cdn.snapi.dev/images/v1/f/k/press12-2487495.jpg)
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
- FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held June 20 th at 8:00 am EDT - WARREN, N.J. , June 20, 2024 /PRNewswire/ -- PTC Therapeutics, In...
![](https://cdn.snapi.dev/images/v1/x/b/conf5-2451361.jpg)
PTC Therapeutics to Participate at Upcoming Investor Conference
WARREN, N.J. , May 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: William Blair's 44th Ann...
![](https://cdn.snapi.dev/images/v1/y/7/press12-2449732.jpg)
PTC Therapeutics Announces Validation of Sepiapterin European MAA
- Review of European marketing application for PKU now initiated - WARREN, N.J. , May 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU ha...
![](https://cdn.snapi.dev/images/v1/9/x/press13-2439238.jpg)
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
- European Commission decides against adoption of negative opinion - - Translarna authorization remains active in Europe - - 2024 revenue guidance paused - WARREN, N.J. , May 20, 2024 /PRNewswire/ -- ...
![](https://cdn.snapi.dev/images/v1/f/a/press2-2429037.jpg)
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
- PDUFA target action date of November 13, 2024 - WARREN, N.J. , May 14, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics L...
![](https://cdn.snapi.dev/images/v1/g/v/conf6-2405823.jpg)
PTC Therapeutics to Participate at Upcoming Investor Conferences
WARREN, N.J. , May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: RBC Capital Markets 2024...
![](https://cdn.snapi.dev/images/v1/z/y/press18-2392554.jpg)
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
– Strong revenue performance across product portfolio – – Submitted MAA for sepiapterin and BLA for Upstaza – – On target to achieve remaining 2024 clinical and regulatory milestones, including globa...
![](https://cdn.snapi.dev/images/v1/f/5/conf4-2367039.jpg)
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
SOUTH PLAINFIELD, N.J., April 11, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 finan...
![](https://cdn.snapi.dev/images/v1/1/o/press20-2346130.jpg)
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
- First marketing authorization submission for sepiapterin with additional global submissions to follow in 2024 - SOUTH PLAINFIELD, N.J. , March 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ...
![](https://cdn.snapi.dev/images/v1/q/i/press9-2341472.jpg)
PTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PTCT
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/x/q/press4-2339450.jpg)
PTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/i/h/press5-2337151.jpg)
PTCT ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your PTC Therapeutics, Inc. investment
NEW YORK, NY / ACCESSWIRE / March 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/t/a/press6-2333924.jpg)
ATTENTION PTCT SHAREHOLDERS: Investors who lost money on PTC Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/a/z/press6-2330670.jpg)
PTC Therapeutics Provides Key Regulatory Updates
- BLA submitted to FDA for Upstaza™ for the treatment of AADC deficiency - - NDA to be submitted mid-year for Translarna™ based on FDA feedback - SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ --...
![](https://cdn.snapi.dev/images/v1/q/9/press8-2325407.jpg)
Levi & Korsinsky Reminds Shareholders of an Investigation into PTC Therapeutics, Inc. (PTCT) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/z/2/press3-2321872.jpg)
PTC Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by PTC (PTCT)
NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/r/b/press15-2319659.jpg)
PTC Therapeutics, Inc. (PTCT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates
NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/3/r/press2-2317509.jpg)
PTCT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PTC Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations o...
![](https://cdn.snapi.dev/images/v1/q/q/press9-2315185.jpg)
ATTENTION PTC Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / March 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of...
![](https://cdn.snapi.dev/images/v1/c/4/press11-2312808.jpg)
ATTENTION PTC Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of...
![](https://cdn.snapi.dev/images/v1/z/e/press14-2310557.jpg)
PTC Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - PTCT
NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of...
![](https://cdn.snapi.dev/images/v1/j/f/press8-2308180.jpg)
Lost Money on PTC Therapeutics, Inc.(PTCT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violations of...
![](https://cdn.snapi.dev/images/v1/k/l/press8-2302323.jpg)
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
– 34% year-over-year growth in 2023 total revenue – – Global filings of sepiapterin remain on track with first submission of the EU MAA expected in March – – Potential NDA submission for vatiquinone...
![](https://cdn.snapi.dev/images/v1/p/x/press11-2296553.jpg)
PTC Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - PTCT
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC") (NASDAQ:PTCT) concerning possible violation...